‼️ #ASCO26 simultaneous publication by Mascarenhas et al:
Selinexor Plus Ruxolitinib in JAK Inhibitor-Naïve Myelofibrosis: Phase 3 SENTRY Trial
Read the full article: https://t.co/qlwEwILG3x
@Komatinsky21199 That’s what I heard from several physicians from Taiwan. There is no practical guideline in using MPN-10 or TSS in real world, it’s not an objective indicator. They only focus on the spleen shrinkage, and they all said any single jak1/2 inhibitor can’t met the needs.
In our latest podcast, Jean-Jacques Kiladjian discusses the key findings from the 12-month primary endpoint analysis of the ROP-ET phase III study, presented at #ASH25.
Listen here: https://t.co/izE6Uv7urt
#MPN#EssentialThrombocythemia#MPNsm#MedEd@jjkiladjian
CONGRESS | #ASH2025 | POSTER
Tiziano Barbui shares real-world findings from a cohort of a prospective, non-interventional, post-authorization study (ROPEG-PV), evaluating ropeginterferon alfa-2b (Ropeg) in patients with polycythemia vera (N = 316).
Hematologic response rates improved from 17.9% at baseline to 50.0% at 24 months, with phlebotomy need also declining. Thrombotic events (n=7), disease progression (n=9), secondary cancer (n=3), and deaths (n=3) were infrequent. A total of 88 AEs were reported, including 12 Grade 3–5 events, with SAEs uncommon. Treatment discontinuation reached 20.9% and 31.8% at 12 months and 24 months, respectively.
Follow our live feed for more updates: https://t.co/Z99bijEUG4
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. A full list of supporters can be found on our website.
#MPN #MPNsm #PolycythemiaVera #MedEd #MedicalCongress @FromBergamo
Sitting here at #ASH25 , I am blown away by the progress in #myeloma in the 21st century. I never thought we could “cure” patients from MM in my lifetime. When I started in the field a quarter century ago, patients would be lucky to make it past 3 years post-diagnosis #mmsm
CONGRESS | #ASH25 | PRESENTATION
Jean-Jacques Kiladjian presents 12-month primary endpoint analysis from the ROP-ET phase 3 study of ropeginterferon alfa-2b in patients with essential thrombocytopenia (N = 132).
The study met its primary endpoint, 48.0% showed a durable disease response. 62.3% of patients experienced symptom improvement, 25.4% had no disease progression.
Safety profile was in live with the experience in PV. TRAEs were mostly mild in 68.9% of patients. Grade ≥3 TRAEs reported in 5.3%. Most common AEs were ALT increase, headache, neutropenia and pruritus.
Follow our live feed for more updates: https://t.co/Z99bijEUG4
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. A full list of supporters can be found on our website.
#MPN #MPNsm #MedEd #MedicalCongress @jjkiladjian@APHP @Univ_Paris